Real-World data reveals how HAE drugs perform in chinese patients
NCT ID NCT06346899
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviewed medical records of 115 Chinese people with hereditary angioedema (HAE) to see how well two approved drugs work in real life. One drug, lanadelumab, is used to prevent attacks, and the other, icatibant, treats sudden attacks. Researchers measured attack rates and how quickly symptoms resolved, while also tracking side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated hospital of Kunming Medical University
Kunming, Yunnan, 650032, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, 450003, China
-
Qianfo Mountain Hospital, Shandong Province
Jinan, Shandong, 250014, China
-
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200011, China
-
Shanxi Bethune hospital
Taiyuan, Shanxi, 030032, China
-
The First Affiliated Hospital ,Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujan, 350005, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510260, China
-
The Second Affiliated hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
-
The Second Affiliated hospital of Xian Jiaotong University
Xian, Shanxi, 710000, China
-
Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology
Wuhan, Hubei, 430030, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- HAE patients and caregivers speak out: the hidden costs of On-Demand treatment
- Real-world study shows lanadelumab keeps HAE attacks at bay for many patients
- Takhzyro under the microscope: Real-World safety check for rare swelling disease
- New hope for HAE patients: experimental drug aims to slash attack rate
- New RNA drug shows promise in preventing HAE attacks in ongoing study
- New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder